Researchers at the Roskamp Institute in Florida recently published a study in the journal Molecular and Cellular Neuroscience revealing that cannabinoids could delay the effects of Alzheimer’s disease, and could quite plausibly terminate the disease entirely.

Corbin Bachmeier, Ph.D, lead researcher of the study, declared that Alzheimer’s disease is “the result of impaired Aβ [Amyloid-β protein] clearance from the brain”. According to this particular study, cannabinoids can resolve this problem, which makes it a prospective treatment.

Bachmeier’s examination determined that “modulation of the cannabinoid system was shown to reduce Aβ [Amyloid-β protein] brain levels and improve cognitive behavior in Alzheimer’s disease animal models.”

The study’s abstract states that the objective of the study was to “investigate the role of the cannabinoid system in the clearance of Aβ across the blood–brain barrier (BBB).”

For the first time in recorded history, the study in question establishes that the cannabinoid system does indeed play a role in the transit of Amyloid-β protein across the blood-brain barrier.

Bachmeier concluded that his discoveries “provide insight into the mechanism by which cannabinoid treatment reduces Aβ [Amyloid-β protein] burden in the AD [Alzheimer’s disease] brain and offer additional evidence on the utility of this pathway as a treatment for AD.”

This is good news for individuals suffering with this specific ailment and for their loved ones. Cannabinoids seem to be boundless in respect to the medicinal benefits they have to offer.

Editorial note: This article was originally published on The 420 Times on July 17, 2013.